HIV update: Emerging clinical evidence and a review of recommendations for the use of highly active antiretroviral therapy

American Journal of Health-System Pharmacy

Volumn 61, Issue SUPPL. 3, 2004, Pages

  Kress, Kendra D ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Antiretroviral agents; Department of Health and Human Services; Drugs; HIV infections; Mechanism of action; Mortality; Protocols; Quality of life; Toxicity

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR;

DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; IMMUNOREACTIVITY; INSULIN RESISTANCE; INTERMETHOD COMPARISON; LIPOATROPHY; LYMPHOCYTE COUNT; MITOCHONDRIAL TOXICITY; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 8344234212     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.suppl_3.s3     Document Type: Review

References (22)

1. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Bethesda, Maryland, March 23, 2004.
2. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338:853-60.
3. Descamps D, Flandre P, Calvez V et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction- maintenance therapy. JAMA. 2000; 283:205-11. [Erratum JAMA. 2000; 284:1518.]
4. Masquelier B, Peytavin G, Leport C et al. Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study. J Infect Dis. 2002; 186 (10):1503-7.
5. Staszewski S, Keiser P, Montaner J et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA. 2001; 285:1155-63. [Erratum, JAMA. 2001; 285:2858.]
6. Vibhagool A, Cahn P, Schechter M et al. Abacavir/combivir is comparable to indinavir/combivir in HIV-1 infected antiretroviral therapy naive adults: preliminary results of a 48-week open label study (CNA 3014). Paper presented at 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina; 2001 July 8-11.
7. Staszewski S, Morales-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999; 341: 1865-73.
8. Bartlett JA, Johnson J, Herrera G et al. Abacavir/lamivudine in combination with efavirenz, amprenavir/ritonavir or d4T: ESS40001 (CLASS) preliminary 48 week results. Paper presented at 14th International AIDS Conference. Barcelona, Spain; 2002 July 7-12.
9. Van Leeuwen R, Katlama C, Murphy RL et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 2003; 17:987-99.
10. Gulick RM, Ribaudo HJ, Shikuma CM et al. ACTG 5095: a comparative study of three protease inhibitor-sparing antiretroviral regimens for the initial treatment of HIV infection. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; 2003 July 13-16.
11. Nassar N, Keiser P, Smillie J et al. An observational cohort comparison of zidovudine-lamivudine-efavirenz to zidovudine-lamivudine-abacavir in antiretroviral naïve individuals. Paper presented at the 2nd International AIDS Society Conference on HIV and Pathogenesis. Paris, France; 2003 July 13-16.
12. Gerstoft J, Kirk O, Obel N et al. Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine, and didanosine. AIDS. 2003; 17:2045-52.
13. Kearney BP, Isaacson E, Sayre J et al. Didanosine and tenofovir DF drug-drug interaction: assessment of didanosine dose reduction. Paper presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2003 February 10-14.
14. Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment naïve, HIV-infected patients receiving a once daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. Paper presented at 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; 2004 February 8-11.
15. Gallant JE, Rodriguez AE, Weinberg W et al. Early non-response to tenofovir DF + abacavir and lamivudine in a randomized trial compared to efavirenz + abacavir and lamivudine: ESS30009. Paper presented at the 43rd Annual ICAAC. Chicago, Illinois; 2003 September 14-17.
16. Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients. Paper presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France; 2003 July 13-16.
17. Hoogewerf M, Regez RM, Schouten WEM et al. Change to abacavir-lamivudine- tenofovir combination treatment in patients with HIV-1 who had complete virologic suppression. Lancet. 2003; 362:1979-80.
18. Landman R, Peytavin G, Descamps D et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: The Tonus Study. Paper presented at the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA; 2004 February 8-11.
19. Elion R, Cohen C, DeJesus E et al. Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, California; 2004 February 8-12.
20. Johnson M, DeWit S, Gazzard B et al. Paper presented at the 9th European AIDS Conference. Warsaw, Poland. 2003 Octtober 25-29.
21. Robbins G, Shafer R, Smeaton L et al. Antiretroviral strategies in naive HIV+ patients: comparison of sequential 3-drug regimens (ACTG 384). Paper presented at the 14th International AIDS Conference. Barcelona, Spain; 2002 July 7-12.
22. Burger D, Hugen P, Reiss P et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 2003; 17: 1157-65.